Roluperidone
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT and σ receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H receptor. As of May 2018, the drug is in phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements".